CM
ABBV icon

Capula Management’s AbbVie ABBV Stock Holding History

Capula Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.44M Sell
25,000
-700
-3% -$155K 0.04% 123
2025
Q4 		$5.87M Sell
25,700
-48,400
-65% -$11M 0.03% 146
2025
Q3 		$17.2M Buy
74,100
+70,200
+1,800% +$14.3M 0.09% 84
2025
Q2 		$724K Sell
3,900
-2,600
-40% -$483K 0.01% 192
2025
Q1 		$1.36M Buy
6,500
+4,300
+195% +$836K 0.01% 224
2024
Q4 		$391K Sell
2,200
-200
-8% -$36.8K ﹤0.01% 191
2024
Q3 		$474K Sell
2,400
-2,900
-55% -$541K ﹤0.01% 253
2024
Q2 		$909K Buy
5,300
+5,000
+1,667% +$828K 0.01% 161
2024
Q1 		$54.6K Buy
+300
New +$51.7K ﹤0.01% 451
2023
Q4 		– Sell
-6,200
Closed -$924K – 291
2023
Q3 		$924K Sell
6,200
-36,500
-85% -$5.36M 0.02% 232
2023
Q2 		$5.75M Sell
42,700
-146,100
-77% -$21.4M 0.14% 87
2023
Q1 		$30.1M Buy
188,800
+106,500
+129% +$16.3M 0.36% 57
2022
Q4 		$13.3M Sell
82,300
-63,000
-43% -$9.66M 0.18% 148
2022
Q3 		$19.5M Buy
145,300
+54,800
+61% +$7.86M 0.26% 108
2022
Q2 		$13.9M Buy
90,500
+38,500
+74% +$5.88M 0.24% 109
2022
Q1 		$8.43M Buy
+52,000
New +$7.55M 0.12% 150
2021
Q4 		– Sell
-130,400
Closed -$13.9M – 172
2021
Q3 		$13.9M Buy
130,400
+90,000
+223% +$10.3M 0.17% 104
2021
Q2 		$4.5M Sell
40,400
-53,500
-57% -$6.03M 0.07% 208
2021
Q1 		$10.2M Buy
93,900
+51,400
+121% +$5.5M 0.2% 131
2020
Q4 		$4.55M Buy
+42,500
New +$4.08M 0.23% 98
2020
Q3 		– Sell
-109,500
Closed -$10.8M – 135
2020
Q2 		$10.8M Sell
109,500
-47,600
-30% -$4.19M 0.38% 64
2020
Q1 		$12M Sell
157,100
-117,900
-43% -$10M 0.43% 62
2019
Q4 		$24.3M Buy
275,000
+200,000
+267% +$16.6M 0.52% 41
2019
Q3 		$5.68M Buy
75,000
+57,500
+329% +$3.94M 0.12% 162
2019
Q2 		$1.27M Buy
+17,500
New +$1.38M 0.26% 81

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capula Management's ABBV Position: Q1 2026 in Review

Capula Management increased its AbbVie (ABBV) stake by 315% in Q1 2026, buying an estimated $1.08M and bringing the position to 6,392 shares worth $1.39M. The position accounts for 0.01% of the portfolio, ranked #308.

Capula Management first reported a position in ABBV in Q2 2019 and has held it in 18 quarters since. The position peaked at $7.03M in Q1 2020. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Capula Management held 6,392 shares of AbbVie worth $1.39M as of Q1 2026.
  • Capula Management bought 4,852 AbbVie shares in Q1 2026, an estimated $1.08M.
  • AbbVie made up 0.01% of Capula Management's portfolio in Q1 2026, its #308 holding.
  • Capula Management first reported a position in AbbVie in Q2 2019 and has held it in 18 quarters since.
  • Capula Management's AbbVie position peaked at $7.03M in Q1 2020.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Capula Management's 13F filing for Q1 2026, filed 14 May 2026.